EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study

Rahul Ladwa iD, Jenny H Lee iD, Margaret McGrath iD, Caroline Cooper iD, Howard Liu, James Bowman, Ruta Gupta, Claire Cuscaden, Michelle Nottage iD, Jonathan R Clark, Dieu Le, Marketa Pauley und 5 weitere

Journal of Clinical Oncology · 10.09.2025 · 43 (26) · 2888-2896

DOI: 10.1200/jco-25-00387 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.09.2025. Verfasst von Rahul Ladwa und 16 weiteren Autor:innen. Beteiligte Einrichtung: Princess Alexandra Hospital, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Squamous Cell, Skin Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The high rates of pathologic complete response (pCR) after neoadjuvant immunotherapy have generated interest for a risk adaptive surgical and radiotherapy-free management approach to reduce morbidity in resectable cutaneous squamous cell carcinoma (cSCC). METHODS We conducted a phase II, multicenter study to evaluate pembrolizumab in patients with resectable stage II-IV (M0) cSCC. Patients received pembrolizumab, administered at a dose of 200 mg once every 3 weeks for four cycles, before undergoing a 18F-labeled fluorodeoxyglucose-positron emission tomography assessment. Patients who achieved a clinical complete response (cCR), defined as a complete metabolic response and negative mapping biopsies of the target site(s), avoided planned surgery and radiotherapy (total de-escalation). In the absence of a cCR, patients underwent surgery with the recommendation of omitting adjuvant radiotherapy (partial de-escalation) on the basis of a pCR. Patients proceeded to 13 additional cycles of maintenance pembrolizumab. The primary end point of a clinical or pathologic complete response (cpCR) was the combined rate of cCR and pCR. Key secondary end points included omission of surgery ± radiotherapy, event-free survival, and adverse events (AEs). RESULTS A total of 27 patients received pembrolizumab. A cpCR was observed in 17 patients (63% [95% CI, 42 to 80), composed of a pCR in four (15%) and a cCR in 13 (48%). Total and partial de-escalation was achieved in 48% and 15%, respectively. With a median follow-up of 18 months, no recurrence was seen in those patients with a cpCR. Treatment-related AEs of grade ≥3 were observed in two patients (7%). There were no treatment-related deaths. CONCLUSION Pembrolizumab led to a high rate of cpCR in resectable cSCC and demonstrated the potential to avoid surgery and radiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Squamous CellSkin NeoplasmsAntineoplastic Agents, ImmunologicalHumansMaleFemaleAgedMiddle AgedAged, 80 and overAdultRadiotherapy, AdjuvantNeoadjuvant Therapy

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Princess Alexandra Hospital, Brisbane, Queensland, Australia.
  • The University of Queensland, Brisbane, Queensland, Australia.
  • Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
  • Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • University of Sydney, Sydney, New South Wales, Australia.
  • Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.

ORCID-Profile: Rahul Ladwa, Jenny H Lee, Margaret McGrath, Caroline Cooper, Michelle Nottage, Arutha Kulasinghe, Jazmina Gonzalez-Cruz, Brett G M Hughes, Benedict Panizza

Zitieren

APA

Ladwa, R., Lee, J. H., McGrath, M., Cooper, C., Liu, H., Bowman, J., Gupta, R., Cuscaden, C., Nottage, M., Clark, J. R., Le, D., Pauley, M., Kulasinghe, A., Gonzalez-Cruz, J., Porceddu, S. V., Hughes, B. G. M., & Panizza, B. (2025). Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study. Journal of Clinical Oncology, 43(26), 2888-2896. https://doi.org/10.1200/jco-25-00387

Vancouver

Ladwa R, Lee JH, McGrath M, Cooper C, Liu H, Bowman J, et al. Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study. Journal of Clinical Oncology. 2025;43(26):2888-2896. doi:10.1200/jco-25-00387

BibTeX
@article{Ladwa2025,
  author = {Ladwa, Rahul and Lee, Jenny H and McGrath, Margaret and Cooper, Caroline and Liu, Howard and Bowman, James and Gupta, Ruta and Cuscaden, Claire and Nottage, Michelle and Clark, Jonathan R and Le, Dieu and Pauley, Marketa and Kulasinghe, Arutha and Gonzalez-Cruz, Jazmina and Porceddu, Sandro V and Hughes, Brett G M and Panizza, Benedict},
  title = {Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {26},
  pages = {2888--2896},
  doi = {10.1200/jco-25-00387}
}
Kostenlos starten →